Canadian Journal of Anesthesia, Vol 39, 476-486, Copyright © 1992 by Canadian Anesthesiologists' Society

ARTICLES

Anaesthesia and myasthenia gravis

A Baraka
Department of Anesthesiology, American University of Beirut, Lebanon.

Myasthenia gravis is an autoimmune disease, resulting from the production of antibodies against the acetylcholine receptors of the endplate. These antibodies reduce the number of active receptors, brought about either by functional block of the receptors, by increased rate of receptor degradation, or by complement-mediated lysis. In myasthenic muscles, the miniature endplate potential amplitude is decreased, and a large proportion of the endplate potentials are subthreshold. Repetitive nerve stimulation results in a decremental response. The disease is frequently associated with morphological abnormalities of the thymus. In young patients, thymic hyperplasia is common while thymoma is more frequent in elderly patients. Medical treatment of myasthenia gravis aims at improving of neuromuscular transmission by anticholinesterases, suppressing the immune system by corticosteroids and immunosuppressants, or by decreasing the circulating antibodies by plasmapheresis. Adults with generalized myasthenia should have a trans-sternal thymectomy. A balanced technique of general anaesthesia which includes the use of muscle relaxants can be safely used, provided neuromuscular transmission is monitored. Myasthenic patients are sensitive to nondepolarizing relaxants but intermediate-acting nondepolarizing relaxants such as atracurium and vecuronium are eliminated rapidly, and can be titrated to achieve the required neuromuscular block that can be completely reversed at the end of surgery. Postoperatively, ventilatory support may be required in high-risk patients. Also, medical treatment may be maintained, tapered or discontinued depending on the outcome of surgery. Thymectomy benefits nearly 96% of patients, 46% develop complete remission and 50% are asymptomatic or improve on therapy.

This article has been cited by other articles:

				N. P. Hirsch Neuromuscular junction in health and disease Br. J. Anaesth., July 1, 2007; 99(1): 132 - 138. [Abstract] [Full Text] [PDF]

				A. Meraouna, G. Cizeron-Clairac, R. L. Panse, J. Bismuth, F. Truffault, C. Tallaksen, and S. Berrih-Aknin The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis Blood, July 15, 2006; 108(2): 432 - 440. [Abstract] [Full Text] [PDF]

				J. Warren and S. K. Sharma Ventilatory support using bilevel positive airway pressure during neuraxial blockade in a patient with severe respiratory compromise. Anesth. Analg., March 1, 2006; 102(3): 910 - 911. [Abstract] [Full Text] [PDF]

				G. Della Rocca, C. Coccia, L. Diana, L. Pompei, M. G. Costa, E. Tomaselli, P. Di Marco, V. Vilardi, and P. Pietropaoli Propofol or sevoflurane anesthesia without muscle relaxants allow the early extubation of myasthenic patients: [L'anesthesie au propofol ou au sevoflurane, sans myorelaxants, permet une extubation precoce chez des patients myastheniques] Can J Anesth, June 1, 2003; 50(6): 547 - 552. [Abstract] [Full Text] [PDF]

				A. De Haes, J. H. Proost, J. B. M. Kuks, D. C. van den Tol, and J. M. K. H. Wierda Pharmacokinetic/Pharmacodynamic Modeling of Rocuronium in Myasthenic Patients Is Improved by Taking into Account the Number of Unbound Acetylcholine Receptors Anesth. Analg., September 1, 2002; 95(3): 588 - 596. [Abstract] [Full Text] [PDF]

				C. Chevalley, A. Spiliopoulos, M. de Perrot, J.-M. Tschopp, and M. Licker Perioperative medical management and outcome following thymectomy for myasthenia gravis Can J Anesth, May 1, 2001; 48(5): 446 - 451. [Abstract] [Full Text] [PDF]

				A. S. Baraka, S. K. Taha, and N. I. Kawkabani Neuromuscular interaction of sevoflurane - cisatracurium in a myasthenic patient Can J Anesth, June 1, 2000; 47(6): 562 - 565. [Abstract] [Full Text] [PDF]